Clinical Trial

The MASTER Study (MAmmary Cancer STatin ER Positive Study)

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 14, 2021 (before its estimated January 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Given the compelling evidence supporting a protective effect of statins on breast cancer recurrence, calls for prospective clinical trials have been expressed. In this trial - the MASTER trial - we hypothesize that the addition of statin treatment to the current breast cancer treatment will improve the prognosis of women with early breast cancer. This trial is designed as follows: a randomized, multicenter, double-blind, placebo-controlled comparison of standard (neo)adjuvant therapy plus placebo versus standard (neo)adjuvant therapy plus atorvastatin in patients with early breast cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-10-22.
Status change: Not Yet Recruiting → Recruiting 2021-01-13
Trial Details
NCT Number NCT04601116
Lead Sponsor Aarhus University Hospital
Collaborators: Rigshospitalet, Denmark, Hospital of Southern Jutland, University of Copenhagen, Bornholms Hospital, Naestved Hospital, Vejle Hospital, Odense University Hospital, Nordsjaellands Hospital, Aalborg University Hospital, Herning Hospital
Conditions Breast Cancer Female, Estrogen Receptor Positive Tumor
Enrollment 3,360 participants
Start Date 2021-01-04
Primary Completion 2025-01-01 (estimated)
Study Completion 2035-01-01 (estimated)
Updated on ClinicalTrials.gov 2021-01-14